Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue SUPPL. 2, 2007, Pages

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cetuximab; Metastases; Monoclonal antibodies; Panitumumab; Rash

Indexed keywords

ANTI ACNE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; SILVER NITRATE; TETRACYCLINE DERIVATIVE;

ADJUVANT THERAPY; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG TARGETING; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HUMAN; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; REVIEW; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 37049006061     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.s.004     Document Type: Article

References (28)

1. Castillo L, Etienne-Grimaldi MC, Fischel JL, et al. Pharmacological background of EGFR targeting. Ann Oncol 2004; 15:1007-12.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monothetapy and cetuximab plus irinotecan in irinotecan-refractory merastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
3. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-90.
4. Tabernero J, Rojo F, Jimenez E, et al. A phase I PK and serial tumor and skin phatmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22(16 suppl):55 (Abstract 770).
5. Hartmann JT, Kroening H, Bokemeyer C, et al. Phase I study of gefitinib in combination with oxaliplatin and weekly 5-FU/FA (FUFOX) for second-/third-line trearment in patients (pts) with metastatic colorectal cancer (CRC). J Clin Oncol 2005; 23(16 suppl):230s (Abstract 3154).
6. Keilholz U, Arnold D, Niederle N, et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. J Clin Oncol 2005; 23(16 suppl):264s (Absrract 3575).
7. Pippas AW, Lenz HJ, Mayer RJ, et al. Analysis of EGFR status in metastatic colorectal cancer parients treated with cetuximab monotherapy. J Clin Oncol 2005; 23(16 suppl):269s (Abstract 3595).
8. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-33.
9. Kies M, Arquette M, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; 21:231 (Abstract 925).
10. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al. Phase II trial of cetuximab in patients with refracrory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
11. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract 7).
12. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targering the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004; 22:2610-6.
13. Van Cutsem E. Rash correlates with tumour response after cetuximab. Presented at: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; September 28-October 1, 2004; Geneva, Swirzerland. Abstract 279.
14. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal catcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
15. Sobrero A, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan vs. irinotecan alone for metastatic colorectal cancer (mCRC) after failing prior oxaliplatin-based therapy: the EPIC trial. Presented at: the 98th Annual Meeting of the American Association of Cancer Research; April 14-18, 2007; Los Angeles, CA.
16. Jonker D, Karapetis C, Moore M, et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and rhe Australasian Gastro-Intestinal Trials Group (AGITG). Presented at: the 98th Annual Meeting of the American Association of Cancer Research; April 14-18, 2007; Los Angeles, CA.
17. Hendlisz A, Van Cutsem E, Peeters M, et al. Treatment effect of panitumumab by skin toxicity severity: results from a phase III randomized controlled trial. Ann Oncol 2006; 17(suppl 9):ix284 (Abstract 983PD).
18. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 2004; 22(14 suppl):248 (Abstract 3511).
19. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
20. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-15.
21. Van Cutsem E, Humblet Y, Gelderblom H, et al. Preliminary results of a cetuximab dose escalation study in randomized metastatic colorectal cancer patients using skin reactions as a predictive factor. Presented at: Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 237.
22. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18 suppl):216 (Abstract 3085).
23. Pfeiffer P, Bjerregaard J, Qvortrup C. Biweekly cetuximab (Cet) and irinotecan (Iri) as third-line therapy in patients with advanced colorectal cancer (ACRC). Presented at: Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 305.
24. Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005; 23(16 suppl):254s (Abstract 3535).
25. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
26. Rosenberg A, Loehrer P, Needle M, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorecral cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:121 (Abstract 536).
27. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 200A; 22(14 suppl):248 (Abstract 3513).
28. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) {+/-} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3509).